Kovack Advisors’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.08M Buy
+26,320
New +$1.06M 0.05% 368
2021
Q3
– Sell
-9,380
Closed -$243K – 719
2021
Q2
$243K Buy
9,380
+120
+1% +$3.1K 0.03% 576
2021
Q1
$237K Buy
+9,260
New +$243K 0.03% 534

Other funds holding FTXH

Kovack Advisors's FTXH Position: Q3 2026 in Review

Kovack Advisors opened a new position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q3 2026: 26,320 shares worth $1.08M. The stake represents 0.05% of the portfolio and ranks #368 among its holdings. This is a return to the name: Kovack Advisors previously reported a position in FTXH as recently as Q2 2021.

Kovack Advisors first reported a position in FTXH in Q1 2021 and has held it in 3 quarters since. 71 funds tracked by Wall St. Rank hold FTXH as of Q3 2026.

  • Kovack Advisors held 26,320 shares of First Trust Nasdaq Pharmaceuticals ETF worth $1.08M as of Q3 2026.
  • First Trust Nasdaq Pharmaceuticals ETF was a new Kovack Advisors position in Q3 2026.
  • First Trust Nasdaq Pharmaceuticals ETF made up 0.05% of Kovack Advisors's portfolio in Q3 2026, its #368 holding.
  • Kovack Advisors first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q1 2021 and has held it in 3 quarters since.
  • 71 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q3 2026.

Based on Kovack Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.